Genelux (GNLX) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 11, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41599
Entity Registrant Name	GENELUX CORPORATION
Entity Central Index Key	0001231457
Entity Tax Identification Number	77-0583529
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2625 Townsgate Road
Entity Address, Address Line Two	Suite 230
Entity Address, City or Town	Westlake Village
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91361
City Area Code	(805)
Local Phone Number	267-9889
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	GNLX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,665,298

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current Assets
Cash	$ 10,338	$ 397
Prepaid expenses and other current assets	1,718	1,495
Total Current Assets	12,056	1,892
Property and equipment, net	617	644
Right of use asset	1,851	1,335
Deferred offering costs		1,568
Other assets	92	92
Total Other Assets	2,560	3,639
TOTAL ASSETS	14,616	5,531
Current Liabilities
Accounts payable and accrued expenses	5,292	6,775
Accrued compensation	2,910	2,852
Accrued interest payable		1,178
Accrued interest payable - director and shareholders	108	3,817
Deferred revenue		170
Warrant liabilities		169
Lease liability, current portion	568	266
Notes payable - shareholders, net of debt discount of $108 in 2022	1,600	992
Convertible notes payable - shareholders, current portion, including $65 and $105 past due, respectively	65	15,407
Total Current Liabilities	10,543	31,626
Long-term Liabilities
Lease liability, long-term portion	1,382	1,164
Convertible notes payable, net of debt discount of $541 in 2022		8,524
Total Long-term Liabilities	1,382	9,688
Total Liabilities	11,925	41,314
Shareholders’ Equity (Deficit)
Preferred stock, Series A through K, par value $0.001, 29,927,994 shares authorized; no shares and 22,094,889 shares issued and outstanding, respectively;		22
Common stock, par value $0.001, 75,000,000 shares authorized; 24,553,470 and 9,126,726 shares issued and outstanding, respectively	25	9
Treasury stock, 433,333 shares, at cost	(433)	(433)
Additional paid-in capital	206,688	154,401
Accumulated other comprehensive income	2	2
Accumulated deficit	(203,591)	(189,784)
Total Shareholders’ Equity (Deficit)	2,691	(35,783)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)	$ 14,616	$ 5,531

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt discount, current		$ 108
Convertible notes payable past due, current	$ 65	105
Debt discount, noncurrent		$ 541
Preferrred stock, par value		$ 22,095
Preferred stock, shares authorized		29,927,994
Preferred stock, shares issued		22,094,889
Preferred stock, shares outstanding		22,094,889
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	24,553,470	9,126,726
Common stock, shares outstanding	24,553,470	9,126,726
Treasury stock, shares	433,333	433,333
Series A Through K Preferred Stock [Member]
Preferrred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	29,927,994	29,927,994
Preferred stock, shares issued	0	22,094,889
Preferred stock, shares outstanding	0	22,094,889

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenues	$ 170
Operating expenses:
Research and development	2,845	2,369
General and administrative	3,787	1,095
Total operating expenses	6,632	3,464
Loss from operations	(6,462)	(3,464)
Other expenses:
Interest expense	(143)	(288)
Debt discount amortization	(649)	(49)
Financing costs	(3,110)
Total other expenses	(3,902)	(337)
NET LOSS	$ (10,364)	$ (3,801)
BASIC AND DILUTED LOSS PER COMMON SHARE	$ (0.53)	$ (0.42)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING -
BASIC AND DILUTED	19,575,631	9,110,376

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows from Operating Activities
Net loss	$ (10,364)	$ (3,801)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	136	138
Right-of-use asset	118	102
Amortization of debt discount	649	49
Stock compensation	227	372
Fair value of restricted stock units	198
Cost of stock option repricing	2,606
Fair value of warrants issued in connection with the conversion of convertible notes payable	3,110
(Increase) Decrease in:
Prepaid expenses and other assets	(223)	377
(Decrease) Increase in:
Accounts payable and accrued expenses	(913)	7
Accrued compensation	58	59
Accrued interest payable	92	142
Deferred revenue	(170)	5,460
Lease liability	(114)	(80)
Net cash provided by (used in) operating activities	(4,590)	2,825
Cash Flows from Investing Activities
Purchases of property and equipment	(109)	(15)
Net cash used in investing activities	(109)	(15)
Cash Flows from Financing Activities
Proceeds from notes payable - shareholders	900
Repayment of notes payable - shareholders	(460)
Repayment of convertible notes payable - shareholders		(130)
Payment of deferred offering costs	(303)
Proceeds from common stock issued for cash in connection with the closing of the IPO	14,503
Net cash provided by (used in) financing activities	14,640	(130)
Net increase in cash	9,941	2,680
Cash beginning of period	397	4,495
Cash end of period	10,338	7,175
Supplemental cash flows disclosures:
Interest paid	50	146
Taxes paid
Supplemental non-cash financing disclosures:
Extension of right-of-use asset and operating lease	649
Reclassification of deferred offering costs to shareholders’ equity	1,871
Reclassification of warrant liabilities to shareholders’ equity	169
Conversion of convertible notes payable, accrued interest and loan fees to shareholders’ equity	29,896
Conversion of preferred stock to common stock	22
Conversion of dividends payable to shareholders’ equity	$ 3,443

Condensed Statements of Shareho

Condensed Statements of Shareholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Series A Through K Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 22	$ 9	$ (433)	$ 151,866	$ 2	$ (184,577)	$ (33,111)
Balance, shares at Dec. 31, 2021	22,094,889	9,110,060	433,333
Stock compensation				372			372
Net loss						(3,801)	(3,801)
Balance at Mar. 31, 2022	$ 22	$ 9	$ (433)	152,238	2	(188,378)	(36,540)
Balance, shares at Mar. 31, 2022	22,094,889	9,110,060	433,333
Balance at Dec. 31, 2022	$ 22	$ 9	$ (433)	154,401	2	(189,784)	(35,783)
Balance, shares at Dec. 31, 2022	22,094,889	9,126,726	(433,333)
Stock compensation				227			227
Net loss						(10,364)	(10,364)
Issuance of common shares upon the closing of the initial public offering, net of offering costs		$ 3		12,629			12,632
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares		2,653,000
Issuance of common shares upon conversion of preferred stock	$ (22)	$ 8		14
Issuance of common shares upon conversion of preferred stock, shares	(22,094,889)	8,355,610
Issuance of common shares upon conversion of convertible notes payable, accrued interest and loan fees		$ 5		29,891			29,896
Issuance of common shares upon conversion of convertible notes payable accrued interest and loan fees, shares		4,134,367
Issuance of common shares upon conversion of preferred stock dividends payable				3,443		(3,443)
Issuance of common shares upon conversion of preferred stock dividends payable, shares		272,101
Fair value of vested restricted stock units				198			198
Cost of stock option repricing				2,606			2,606
Reclassification of warrant liabilities upon the closing of the initial public offering				169			169
Fair value of warrants issued in connection with the conversion of convertible notes payable				3,110			3,110
Shares issued upon cashless exercise of stock warrant
Shares issued upon cashless exercise of stock warrant, shares		11,666
Balance at Mar. 31, 2023		$ 25	$ (433)	$ 206,688	$ 2	$ (203,591)	$ 2,691
Balance, shares at Mar. 31, 2023		24,553,470	(433,333)

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1 – BASIS OF PRESENTATION Organization and Operations Genelux Corporation (“Genelux” or the “Company”), a Delaware Corporation, incorporated on September 4, 2001, is a biomedical company located in Westlake Village, California. The Company is engaged in the research and development of diagnostic and therapeutic solutions for cancer for which there is no effective treatment today. The Company is focused on the development of therapeutic approaches for cancer that are designed to generate a personalized multi-prong attack to overwhelm a tumor’s sophisticated defense mechanisms. Basis of Presentation of Unaudited Financial Information The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. COVID-19 Considerations During the three months ended March 31, 2023, the COVID-19 pandemic did not have a material net impact on our operating results, but did have an impact on our supply chain. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our office, clinical trial sites and third parties on whom we rely. Our ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the onset of the COVID-19 pandemic, we maintained the consistency of our operations. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example, an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations. We anticipate that our clinical development timelines could be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition and results of operations. Through March 31, 2023, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date. During the three months ended March 31, 2023, the Company generated cash flows primarily through the closing of its initial public offering of its common stock (“IPO”) to meet its short-term liquidity needs, but it expects to maintain access to other potential loans and equity financings, when needed, and potentially future payments under existing and new licensing agreements. The Company has not observed any material impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, the Company incurred a net loss of $ 10,364 and used cash in operations of $ 4,590 during the three months ended March 31, 2023, and had an accumulated deficit of $ 203,591 In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2022 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. At March 31, 2023, the Company had cash on hand in the amount of $ 10,338 . The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through equity and debt financings, and licensing income, and it expects to continue to rely on these sources of capital in the future. During the three months ended March 31, 2023, the Company closed its IPO and received net proceeds of $ 12,632 1,665,213 20.00 33,300 1,500 15,000 No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing, or grant unfavorable terms in licensing future licensing agreements. Reverse Stock Split In August 2022, the Company effected a 1-for-3 reverse stock split

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates. Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the three months ended March 31, 2023 and 2022, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially dilutive securities consisted of the following: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES March 31, March 31, Convertible notes payable - 3,312,696 Common stock equivalent of Series A through K convertible preferred stock - 8,558,947 Stock options 4,201,019 3,962,074 Stock warrants 1,034,979 823,129 Restricted stock units 113,500 - Stock warrants, issuable in connection with conversion of notes payable 69,893 183,852 Total 5,419,391 16,840,698 Revenue Recognition The Company records revenue under the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) The Company determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Under certain of the Company’s licensing, supply and collaboration agreements, it is entitled to receive payment upon the achievement of contingent milestone events or the performance of obligations. The Company recognizes revenue based on guidance in ASC 606. In evaluating revenue recognition under a license agreement, the Company uses a two-step process for determining whether a promised good or service (including a license of intellectual property) is distinct and, therefore, is a performance obligation: (1) consideration of the individual good or service (i.e., whether the good or service is capable of being distinct); and (2) consideration of whether the good or service is separately identifiable from other promises in the contract (i.e., whether the promise to transfer the good or service is distinct in the context of the contract). Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s balance sheet. Amounts expected to be recognized as revenue in the next 12 months following the balance sheet date are classified as current liabilities. During the year ended December 31, 2022, the Company, under its Newsoara agreement, invoiced and collected $170 relating to supplying product for Newsoara to use in their clinical trials. As the product did not ship during the year ended December 31, 2022, the Company recorded the cash received as deferred revenue until the product was shipped. During the three months ended March 31, 2023, the Company shipped the product to Newsoara and thus recognized the revenue. Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December 31, 2022, the Company incurred $ 1,568 303 1,871 Fair Value of Financial Instruments The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amount of the Company’s warrant liabilities of $ 169 Stock-Based Compensation The Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these awards using the straight-line method over the requisite service period. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. The Company was a private company until the completion of its IPO on January 30, 2023. In 2022 and prior, the Company estimated the fair value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties in arms’ length transactions, the rights and preferences of securities senior to the Company’s common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options at each valuation date, as applicable. The fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses—Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for the Company beginning January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial position, results of operations, and cash flows. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. ASU 2021-04 provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. The adoption of ASU 2021-04 did not have a material impact on the Company’s financial statements or disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 - PROPERTY AND EQUIPMENT Property and equipment consisted of the following at March 31, 2023 and December 31, 2022: SCHEDULE OF PROPERTY AND EQUIPMENT March 31, December 31, Furniture and office equipment $ 148 $ 148 Laboratory equipment 2,762 2,762 Computer equipment 127 127 Leasehold improvements 557 557 Construction-in-progress 109 - Property and equipment, gross 3,703 3,594 Less: accumulated depreciation and amortization (3,086 ) (2,950 ) Property and equipment, net $ 617 $ 644 Depreciation expense for the three months ended March 31, 2023 and 2022 was $ 136 138

ACCRUED COMPENSATION

ACCRUED COMPENSATION	3 Months Ended
	Mar. 31, 2023
Accrued Compensation
ACCRUED COMPENSATION	NOTE 4 – ACCRUED COMPENSATION As of March 31, 2023 and December 31, 2022, the Company had accrued compensation owed to the Company’s Chief Executive Officer, another employee and two former employees that had accrued over a several year period. As of March 31, 2023 and December 31, 2022, a total of $ 2,910 2,852

LEASE LIABILITIES

LEASE LIABILITIES	3 Months Ended
	Mar. 31, 2023
Lease Liabilities
LEASE LIABILITIES	NOTE 5 – LEASE LIABILITIES Operating Leases The Company accounts for leases in accordance with ASC 842, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. In July 2018, the Company entered into a long-term non-cancellable lease agreement for its manufacturing facility that requires aggregate average monthly payments of $ 10 option to extend for an additional five years. 518 519 4.00 Effective April 2022, the Company extended the lease for the additional five-year period, with no changes to any of the other terms of the lease, the option to extend the lease for an additional five years Prior to the extension, the remaining lease liability amounted to $ 174 860 4.00 686 In December 2020, the Company entered into a long-term non-cancellable lease agreement for a laboratory facility that requires aggregate average monthly payments of $ 18 439 4.00 Effective February 2023, the Company extended the lease through December 2024, with no changes to any of the other terms of the lease 30 Prior to the extension, the remaining lease liability amounted to $ 12 649 5.5 637 In July 2021, the Company entered into a long-term non-cancellable lease agreement for its new corporate headquarters that requires aggregate average monthly payments of $ 10 656 4.00 During the three months ended March 31, 2023 and 2022, the Company made combined aggregate payments of $ 114 80 1,950 1,164 ASC 842 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. During the three months ended March 31, 2023 and 2022, the Company reflected combined amortization of the right of use assets of $ 118 102 1,851 1,335 Other Leases In November 2019, the Company entered into a short-term lease agreement for one of its office facilities, extending the lease until December 2020, and in October 2020, it was extended until December 2021. In November 2021, it was extended again for one year until December 2022. The lease for this facility is currently on a month-to-month basis. Rent expense was $ 9

NOTES PAYABLE _ SHAREHOLDERS

NOTES PAYABLE – SHAREHOLDERS	3 Months Ended
	Mar. 31, 2023
Notes Payable Shareholders
NOTES PAYABLE – SHAREHOLDERS	NOTE 6 – NOTES PAYABLE – SHAREHOLDERS During the year ended December 31, 2022 , the Company, in anticipation of closing its IPO, entered into note payable agreements with several shareholders totaling $ 1,100 12 1,100 5 During the three months ended March 31, 2023, the Company extended the due date on the notes until April 30, 2023. During the three months ended March 31, 2023, 900 repaid $ 400 1 47 1,600 51 In consideration for the notes, the Company issued the note holders stock warrants to purchase up to an aggregate total of 44,441 169 using a Black Scholes option pricing model with the following assumptions: SCHEDULE OF WARRANTS Exercise price $ 6.00 Expected dividends — Expected volatility 96.0 % Risk free interest rate 3.50 % Life of the warrants 3.0 The Company recognized a liability and recorded a debt discount at the date of issuance in the amount of $ 169 61 108 108 no

CONVERTIBLE NOTES PAYABLE _ SHA

CONVERTIBLE NOTES PAYABLE – SHAREHOLDERS	3 Months Ended
	Mar. 31, 2023
Convertible Notes Payable Shareholders
CONVERTIBLE NOTES PAYABLE – SHAREHOLDERS	NOTE 7 – CONVERTIBLE NOTES PAYABLE – SHAREHOLDERS Convertible notes payable to shareholders consisted of the following as of March 31, 2023 and December 31, 2022: SCHEDULE OF CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS March 31, December 31, Convertible notes payable - shareholders (a) $ 65 $ 7,838 Convertible note payable - shareholder (b) — 1,500 Convertible notes payable – shareholders (c) — 700 Convertible notes payable - shareholders (d) — 5,369 Convertible notes payable - shareholders 65 15,407 Less: current portion (65 ) (15,407 ) Convertible notes payable – shareholders – long - term portion $ — $ — (a) During the years ended December 31, 2011 through 2016, the Company entered into convertible note payable agreements with individuals aggregating to a total amount of $ 7,988 8 25.73 As of December 31, 2022, the principal amount due on the notes aggregated to $ 7,838 2,890 During the three months ended March 31, 2023, $ 60 36 13 7,778 2,867 Upon the closing of the IPO, all of the principal plus accrued and unpaid interest, except for $ 65 58 1,554,814 6.78 As of March 31, 2023, total principal of $ 65 58 8 (b) In April 2016, the Company entered into a convertible note payable agreement with a shareholder in the amount of $ 2,661 11.51 6.78 10 6.78 As of December 31, 2022, total principal of $ 1,500 560 10 1,500 570 Upon the closing of the IPO, all of the principal plus accrued and unpaid loan fees automatically converted into 303,835 6.78 may issue 55,310 9.00 (c) In April 2018, the Company entered into two convertible note payable agreements with a shareholder under which the Company borrowed an aggregate total of $ 700 5.0 12.00 90 25 10.50 three years As of December 31, 2022, total principal of $ 700 164 3 700 167 Upon the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into 160,563 5.40 90 may issue 14,583 10.50 (d) During the years ended December 31, 2019 through 2021, the Company entered into convertible note payable agreements with several shareholders under which the Company borrowed an aggregate amount of $ 5,369 5.0 12.00 90 25 10.50 three years As of December 31, 2022, total principal of $ 5,369 758 22 5,369 780 Upon the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into 1,134,063 5.40 90 During the three months ended March 31, 2023, 111,828 10.50

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 8 – CONVERTIBLE NOTES PAYABLE Convertible notes payable consisted of the following as of March 31, 2023 and December 31, 2022: SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, December 31, Convertible note payable $ — $ 9,065 Less: debt discount — (541 ) Convertible notes payable, net $ — $ 8,524 During the years ended December 31, 2020 and 2021, the Company entered into convertible note payable agreements with an investing group under which the Company borrowed an aggregate amount of $ 9,065 6.0 10.50 146,641 10.50 As of December 31, 2022, the Company owed $ 9,065 1,178 45 9,065 1,223 The Company calculated the relative fair value of the warrants issued to the noteholder and recognized a debt discount at the date of issuance. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the note (a valuation debt discount). As of December 31, 2022, the notes had an unamortized debt discount balance of $ 541 541 no Upon the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into 979,619 10.50

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 9 - SHAREHOLDERS’ EQUITY Preferred Stock As of December 31, 2022, authorized shares and shares issued and outstanding of the Company’s preferred stock by series were as follows: SCHEDULE OF PREFERRED STOCK Authorized Issued and Par Series A Preferred Stock 4,500,000 4,500,000 4,500 Series B Preferred Stock 608,000 608,000 608 Series C Preferred Stock 5,000,000 5,000,000 5,000 Series D Preferred Stock 3,000,000 3,000,000 3,000 Series E Preferred Stock 1,591,994 1,591,994 1,592 Series F Preferred Stock 953,000 953,000 953 Series H Preferred Stock 5,000,000 536,000 536 Series I Preferred Stock 2,775,000 2,757,442 2,757 Series J Preferred Stock 2,500,000 1,281,600 1,282 Series K Preferred Stock 4,000,000 1,866,853 1,867 Total 29,927,994 22,094,889 22,095 Upon the closing of the Company’s IPO on January 30, 2023, all of the Company’s 22,094,889 8,355,610 991,172 As of January 30, 2023, earned but undeclared and unpaid Series H dividends were $ 3,443 272,101 Common Stock Authorized shares The Company’s Certificate of Incorporation authorizes the Company to issue up to 75,000,000 24,553,470 9,126,726 Common Stock Issued for Cash Upon Closing of the Company’s IPO On January 30, 2023, the Company completed its IPO of its common stock in which the Company issued and sold 2,500,000 6.00 153,000 6.00 15,918 12,632 Adoption of Equity Incentive Plan and Employee Stock Purchase Plan In June 2022, the Board of Directors adopted the 2022 Equity Incentive Plan (the “2022 Plan”). The stockholders approved the 2022 Plan in August 2022, and it became effective upon its approval by the Company’s stockholders, but no grants could be made under the 2022 Plan until immediately prior to the execution of the underwriting agreement related to the IPO. Under the 2022 Plan, the Company may grant incentive stock options to employees, including employees of any parent or subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of the Company’s affiliates. The 2022 Plan is a successor to the 2019 Plan. A total of 2,800,000 5 In June 2022, the Board of Directors adopted the 2022 Employee Stock Purchase Plan (the “ESPP”). The stockholders approved the ESPP in August 2022, and it became effective immediately prior to the execution of the underwriting agreement for the IPO. A total of 770,000 1% 2,100,000 Grant of Restricted Stock Units (RSU) The following table summarizes restricted common stock activity during the three months ended March 31, 2023: SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY Number of Restricted Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, December 31, 2022 - $ - $ - Granted 113,500 746 6.57 Vested - (198 ) 6.57 Forfeited - - - Non-vested, March 31, 2023 113,500 $ 548 $ 6.57 On February 17, 2023, the Company’s Board of Directors approved the issuance of a combined total of 113,500 746 During the three months ended March 31, 2023, the Company recorded $ 198 548 Stock Options In August 2009, the Company’s Board of Directors approved the adoption of the 2009 Equity Incentive Plan (“the 2009 Plan”). The 2009 Plan was initiated to encourage and enable employees, directors and consultants of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 6,166,666 In September 2018, the Company’s Board of Directors approved the adoption of the 2019 Equity Incentive Plan (“the 2019 Plan”). The 2019 Plan was initiated to encourage and enable employees, directors and consultants of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. The 2019 Plan allows for the following types of awards: (i) Incentive Stock Options; (ii) Nonstatutory Stock Options; (iii) Stock Appreciation Rights; (iv) Restricted Stock Awards; (v) Restricted Stock Unit Awards; (vi) Other Stock Awards. The maximum number of shares of our common stock that may be issued under our 2019 Plan is 2,059,073 3,774,260 5,833,333 1,632,314 2,800,000 Option exercise prices are set forth in the Grant Notice, without commission or other charge, provided however, that the price per share of the shares subject to the option shall not be less than the greater of (i) 100% of the fair market value of a share of stock on the grant date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company. The Company’s policy is to recognize compensation cost for awards with only service conditions on a straight- line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share-based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. The table below summarizes the Company’s stock option activities for the three months ended March 31, 2023: SCHEDULE OF STOCK OPTION ACTIVITY Number of Exercise Weighted Average Balance, December 31, 2022 4,201,019 $ 6.00 10.50 $ 6.09 Granted — — — Cancelled — — — Exercised — — — Expired — — — Balance, March 31, 2023 4,201,019 $ 6.00 10.50 $ 6.09 09 Vested and exercisable, March 31, 2023 4,012,963 $ 6.00 10.50 $ 6.26 Unvested, March 31, 2023 188,056 $ 6.00 $ 6.00 The following table summarizes information concerning outstanding and exercisable options as of March 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS Options Outstanding Options Exercisable Range of Exercise Prices Number Average Weighted Number Average Weighted $ 6.00 4,092,887 5.28 $ 6.00 3,904,831 5.11 $ 6.00 9.00 10.50 108,132 4.80 9.67 108,132 4.80 9.67 $ 6.00 10.50 4,201,019 5.27 $ 6.09 4,012,963 5.11 $ 6.26 In September 2022, the Company’s board of directors approved a stock option repricing whereby the exercise prices of previously granted and unexercised options held by certain employees, directors and key advisers with exercise prices between $ 9.00 10.50 4,092,887 9.00 10.50 6.00 2,796,400 2,733 2,606 During the three months ended March 31, 2023, the Company recorded $ 227 1,751 90,933 At the time of the issuances of stock options, the Company believed the Company’s estimates of the fair value for financial reporting purposes of the Company’s common stock were reasonable and consistent with the Company’s understanding of how similarly situated companies in the industry were valued. Stock Warrants The table below summarizes the Company’s warrants activities for the three months ended March 31, 2023: SCHEDULE OF WARRANTS ACTIVITY Number of Exercise Weighted Average Balance, December 31, 2022 725,174 $ 3.00 10.50 $ 8.24 Granted 331,269 5.40 10.50 7.44 Cancelled (36 ) 9.00 9.00 Exercised (16,666 ) 9.00 9.00 Expired (4,762 ) 10.50 10.50 Balance, March 31, 2023 1,034,979 $ 3.00 10.50 $ 7.96 Vested and exercisable, March 31, 2023 1,034,979 $ 3.00 10.50 $ 7.96 The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Average Weighted Number Average Weighted $ 3.00 133,333 3.92 $ 3.00 133,333 3.92 $ 3.00 5.40 9.00 627,940 3.19 7.91 627,940 3.19 7.91 10.50 273,706 1.41 10.50 273,706 1.41 10.50 $ 3.00 10.50 1,034,979 2.82 $ 7.96 1,034,979 2.82 $ 7.96 Upon the closing of the IPO, the Company agreed to issue to the underwriters, warrants entitling them to purchase up to 175,000 6.00 During the three months ended March 31, 2023, the Company granted warrants to certain of its lenders to purchase up to 44,441 5.40 During the three months ended March 31, 2023, the Company granted warrants to certain of its lenders to purchase up to 111,828 10.50 25 of the shares converted, with exercise prices ranging from 9.00 10.50 per share. The warrants, if issued, will expire over various periods from the date of grant, but none exceeding ten years. The maximum total number of warrant shares that could be granted is 69,893 The Company calculated the aggregate fair value of the warrants on the date of grant to be $ 3,110 111,828 1,174 During the three months ended March 31, 2023, a warrant holder completed a cashless exercise of their stock warrant. The holder exercised 16,666 9.00 11,666 The aggregate intrinsic value for warrant shares outstanding at March 31, 2023 was $ 13,745

LEGAL MATTERS

LEGAL MATTERS	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
LEGAL MATTERS	NOTE 10 - LEGAL MATTERS We are currently involved in one pending litigation. Although the results of the pending legal proceeding in which we currently are involved cannot be predicted with certainty, we do not believe that there is a reasonable possibility that the final outcome of this matter will have a material adverse effect on our business or financial results. Regardless of the final outcome, however, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, harm to our reputation and brand, and other factors. We are not currently a party, nor have we received threat or notice that we will be a party, to any other legal proceedings. In the future, we may be involved in additional actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy and data protection, privacy and other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 - SUBSEQUENT EVENTS On May 12, 2023, the Company entered into a Securities Purchase Agreement, or the Purchase Agreement, with certain investors, or the Purchasers, pursuant to which the Company agreed to sell and issue 1,665,213 20.00 33,300 1,500 15,000 Subsequent to March 31, 2023, the Company repaid one of its bridge loans (see Note 6) totaling $ 210 200 10 Subsequent to March 31, 2023, warrants to purchase 111,828 1,174

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.
Income (Loss) Per Share	Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the three months ended March 31, 2023 and 2022, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially dilutive securities consisted of the following: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES March 31, March 31, Convertible notes payable - 3,312,696 Common stock equivalent of Series A through K convertible preferred stock - 8,558,947 Stock options 4,201,019 3,962,074 Stock warrants 1,034,979 823,129 Restricted stock units 113,500 - Stock warrants, issuable in connection with conversion of notes payable 69,893 183,852 Total 5,419,391 16,840,698
Revenue Recognition	Revenue Recognition The Company records revenue under the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) The Company determines revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Under certain of the Company’s licensing, supply and collaboration agreements, it is entitled to receive payment upon the achievement of contingent milestone events or the performance of obligations. The Company recognizes revenue based on guidance in ASC 606. In evaluating revenue recognition under a license agreement, the Company uses a two-step process for determining whether a promised good or service (including a license of intellectual property) is distinct and, therefore, is a performance obligation: (1) consideration of the individual good or service (i.e., whether the good or service is capable of being distinct); and (2) consideration of whether the good or service is separately identifiable from other promises in the contract (i.e., whether the promise to transfer the good or service is distinct in the context of the contract). Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s balance sheet. Amounts expected to be recognized as revenue in the next 12 months following the balance sheet date are classified as current liabilities. During the year ended December 31, 2022, the Company, under its Newsoara agreement, invoiced and collected $170 relating to supplying product for Newsoara to use in their clinical trials. As the product did not ship during the year ended December 31, 2022, the Company recorded the cash received as deferred revenue until the product was shipped. During the three months ended March 31, 2023, the Company shipped the product to Newsoara and thus recognized the revenue.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December 31, 2022, the Company incurred $ 1,568 303 1,871
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amount of the Company’s warrant liabilities of $ 169
Stock-Based Compensation	Stock-Based Compensation The Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these awards using the straight-line method over the requisite service period. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. The Company was a private company until the completion of its IPO on January 30, 2023. In 2022 and prior, the Company estimated the fair value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties in arms’ length transactions, the rights and preferences of securities senior to the Company’s common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options at each valuation date, as applicable. The fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses—Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for the Company beginning January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial position, results of operations, and cash flows. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. ASU 2021-04 provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. An issuer measures the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange. ASU 2021-04 introduces a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021. The adoption of ASU 2021-04 did not have a material impact on the Company’s financial statements or disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES	SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES March 31, March 31, Convertible notes payable - 3,312,696 Common stock equivalent of Series A through K convertible preferred stock - 8,558,947 Stock options 4,201,019 3,962,074 Stock warrants 1,034,979 823,129 Restricted stock units 113,500 - Stock warrants, issuable in connection with conversion of notes payable 69,893 183,852 Total 5,419,391 16,840,698

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT March 31, December 31, Furniture and office equipment $ 148 $ 148 Laboratory equipment 2,762 2,762 Computer equipment 127 127 Leasehold improvements 557 557 Construction-in-progress 109 - Property and equipment, gross 3,703 3,594 Less: accumulated depreciation and amortization (3,086 ) (2,950 ) Property and equipment, net $ 617 $ 644

NOTES PAYABLE _ SHAREHOLDERS (T

NOTES PAYABLE – SHAREHOLDERS (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Payable Shareholders
SCHEDULE OF WARRANTS	SCHEDULE OF WARRANTS Exercise price $ 6.00 Expected dividends — Expected volatility 96.0 % Risk free interest rate 3.50 % Life of the warrants 3.0

CONVERTIBLE NOTES PAYABLE _ S_2

CONVERTIBLE NOTES PAYABLE – SHAREHOLDERS (Tables)	3 Months Ended
	Mar. 31, 2023
Convertible Notes Payable Shareholders
SCHEDULE OF CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS	Convertible notes payable to shareholders consisted of the following as of March 31, 2023 and December 31, 2022: SCHEDULE OF CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS March 31, December 31, Convertible notes payable - shareholders (a) $ 65 $ 7,838 Convertible note payable - shareholder (b) — 1,500 Convertible notes payable – shareholders (c) — 700 Convertible notes payable - shareholders (d) — 5,369 Convertible notes payable - shareholders 65 15,407 Less: current portion (65 ) (15,407 ) Convertible notes payable – shareholders – long - term portion $ — $ — (a) During the years ended December 31, 2011 through 2016, the Company entered into convertible note payable agreements with individuals aggregating to a total amount of $ 7,988 8 25.73 As of December 31, 2022, the principal amount due on the notes aggregated to $ 7,838 2,890 During the three months ended March 31, 2023, $ 60 36 13 7,778 2,867 Upon the closing of the IPO, all of the principal plus accrued and unpaid interest, except for $ 65 58 1,554,814 6.78 As of March 31, 2023, total principal of $ 65 58 8 (b) In April 2016, the Company entered into a convertible note payable agreement with a shareholder in the amount of $ 2,661 11.51 6.78 10 6.78 As of December 31, 2022, total principal of $ 1,500 560 10 1,500 570 Upon the closing of the IPO, all of the principal plus accrued and unpaid loan fees automatically converted into 303,835 6.78 may issue 55,310 9.00 (c) In April 2018, the Company entered into two convertible note payable agreements with a shareholder under which the Company borrowed an aggregate total of $ 700 5.0 12.00 90 25 10.50 three years As of December 31, 2022, total principal of $ 700 164 3 700 167 Upon the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into 160,563 5.40 90 may issue 14,583 10.50 (d) During the years ended December 31, 2019 through 2021, the Company entered into convertible note payable agreements with several shareholders under which the Company borrowed an aggregate amount of $ 5,369 5.0 12.00 90 25 10.50 three years As of December 31, 2022, total principal of $ 5,369 758 22 5,369 780 Upon the closing of the IPO, all of the principal plus accrued and unpaid interest automatically converted into 1,134,063 5.40 90 During the three months ended March 31, 2023, 111,828 10.50

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	Convertible notes payable consisted of the following as of March 31, 2023 and December 31, 2022: SCHEDULE OF CONVERTIBLE NOTES PAYABLE March 31, December 31, Convertible note payable $ — $ 9,065 Less: debt discount — (541 ) Convertible notes payable, net $ — $ 8,524

SHAREHOLDERS_ EQUITY (Tables)

SHAREHOLDERS’ EQUITY (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SCHEDULE OF PREFERRED STOCK	As of December 31, 2022, authorized shares and shares issued and outstanding of the Company’s preferred stock by series were as follows: SCHEDULE OF PREFERRED STOCK Authorized Issued and Par Series A Preferred Stock 4,500,000 4,500,000 4,500 Series B Preferred Stock 608,000 608,000 608 Series C Preferred Stock 5,000,000 5,000,000 5,000 Series D Preferred Stock 3,000,000 3,000,000 3,000 Series E Preferred Stock 1,591,994 1,591,994 1,592 Series F Preferred Stock 953,000 953,000 953 Series H Preferred Stock 5,000,000 536,000 536 Series I Preferred Stock 2,775,000 2,757,442 2,757 Series J Preferred Stock 2,500,000 1,281,600 1,282 Series K Preferred Stock 4,000,000 1,866,853 1,867 Total 29,927,994 22,094,889 22,095
SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY	The following table summarizes restricted common stock activity during the three months ended March 31, 2023: SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY Number of Restricted Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, December 31, 2022 - $ - $ - Granted 113,500 746 6.57 Vested - (198 ) 6.57 Forfeited - - - Non-vested, March 31, 2023 113,500 $ 548 $ 6.57
SCHEDULE OF STOCK OPTION ACTIVITY	The table below summarizes the Company’s stock option activities for the three months ended March 31, 2023: SCHEDULE OF STOCK OPTION ACTIVITY Number of Exercise Weighted Average Balance, December 31, 2022 4,201,019 $ 6.00 10.50 $ 6.09 Granted — — — Cancelled — — — Exercised — — — Expired — — — Balance, March 31, 2023 4,201,019 $ 6.00 10.50 $ 6.09 09 Vested and exercisable, March 31, 2023 4,012,963 $ 6.00 10.50 $ 6.26 Unvested, March 31, 2023 188,056 $ 6.00 $ 6.00
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS	The following table summarizes information concerning outstanding and exercisable options as of March 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS Options Outstanding Options Exercisable Range of Exercise Prices Number Average Weighted Number Average Weighted $ 6.00 4,092,887 5.28 $ 6.00 3,904,831 5.11 $ 6.00 9.00 10.50 108,132 4.80 9.67 108,132 4.80 9.67 $ 6.00 10.50 4,201,019 5.27 $ 6.09 4,012,963 5.11 $ 6.26
SCHEDULE OF WARRANTS ACTIVITY	The table below summarizes the Company’s warrants activities for the three months ended March 31, 2023: SCHEDULE OF WARRANTS ACTIVITY Number of Exercise Weighted Average Balance, December 31, 2022 725,174 $ 3.00 10.50 $ 8.24 Granted 331,269 5.40 10.50 7.44 Cancelled (36 ) 9.00 9.00 Exercised (16,666 ) 9.00 9.00 Expired (4,762 ) 10.50 10.50 Balance, March 31, 2023 1,034,979 $ 3.00 10.50 $ 7.96 Vested and exercisable, March 31, 2023 1,034,979 $ 3.00 10.50 $ 7.96
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS	The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2023: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Average Weighted Number Average Weighted $ 3.00 133,333 3.92 $ 3.00 133,333 3.92 $ 3.00 5.40 9.00 627,940 3.19 7.91 627,940 3.19 7.91 10.50 273,706 1.41 10.50 273,706 1.41 10.50 $ 3.00 10.50 1,034,979 2.82 $ 7.96 1,034,979 2.82 $ 7.96

SCHEDULE OF CONVERTIBLE NOTES P

SCHEDULE OF CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS (Details) (Parenthetical) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended
	Jan. 30, 2023	May 31, 2018	Mar. 31, 2023		May 15, 2023	May 12, 2023	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2019	Apr. 30, 2018	Dec. 31, 2016	Apr. 30, 2016
Subsidiary, Sale of Stock [Line Items]
Principal amount owed on notes			$ 65				$ 15,407
Accrued interest			10
Convertible Notes Payable Shareholder One [Member]
Subsidiary, Sale of Stock [Line Items]
Principal amount owed on notes	$ 7,778		$ 65	[1]			7,838	[1]				$ 7,988
Accrued interest percentage			8%									8%
Conversion price	$ 6.78
Accrued and unpaid interest	$ 2,867		$ 58				2,890
Repayment of debt			60
Payment on accrued and unpaid interest			36
Accrued interest			13
Notes payable	65
Nonconvertible accrued and unpaid interest	$ 58
Conversion of common stock	1,554,814
Convertible Notes Payable Shareholder One [Member] | Series K Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price												$ 25.73
Convertible Notes Payable Shareholder Two [Member]
Subsidiary, Sale of Stock [Line Items]
Principal amount owed on notes	$ 1,500			[2]			1,500	[2]					$ 2,661
Accrued interest percentage													11.51%
Conversion price	$ 6.78	$ 6.78											$ 6.78
Conversion of common stock	303,835
Accrued loan fees		$ 10	10
Accrued and unpaid loan fees owed on notes	$ 570						560
Convertible Notes Payable Shareholder Three [Member]
Subsidiary, Sale of Stock [Line Items]
Principal amount owed on notes	$ 700			[3]			700	[3]			$ 700
Accrued interest percentage											5%
Conversion price	$ 5.40										$ 12
Accrued and unpaid interest	$ 167						164
Accrued interest			3
Conversion of common stock	160,563
Warrants exercise price											$ 10.50
Initial public offering closing price	90%										90%
Warrants to purchase shares, percentage											25%
Warrants term											3 years
Convertible Notes Payable Shareholder Four [Member]
Subsidiary, Sale of Stock [Line Items]
Principal amount owed on notes	$ 5,369			[4]			5,369	[4]	$ 5,369
Accrued interest percentage									5%
Conversion price	$ 5.40								$ 12
Accrued and unpaid interest	$ 780						$ 758
Accrued interest			$ 22
Conversion of common stock	1,134,063
Warrants to purchase shares			111,828
Warrants exercise price			$ 10.50						$ 10.50
Initial public offering closing price	90%									90%
Warrants to purchase shares, percentage									25%
Warrants term									3 years
Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares					111,828
Subsequent Event [Member] | Convertible Notes Payable Shareholder Two [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares					55,310
Warrants exercise price					$ 9
Subsequent Event [Member] | Convertible Notes Payable Shareholder Three [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase shares					14,583
Warrants exercise price					$ 10.50
Private Placement [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Principal amount owed on notes						$ 1,500
[1]During the years ended December 31, 2011 through 2016, the Company entered into convertible note payable agreements with individuals aggregating to a total amount of $ 7,988 8 25.73 2,661 11.51 6.78 10 6.78 700 5.0 12.00 90 25 10.50 three years 5,369 5.0 12.00 90 25 10.50 three years

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	May 12, 2023	Aug. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Net income (loss)			$ 10,364,000	$ 3,801,000
Cash used in operations			4,590,000	$ (2,825,000)
Accumulated deficit			203,591,000		$ 189,784,000
Cash and Cash Equivalents, at Carrying Value			10,338,000		$ 397,000
Proceeds from Issuance Initial Public Offering			$ 12,632,000
Reverse stock split		1-for-3 reverse stock split
Private Placement [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Shares, Issued	1,665,213
Share Price	$ 20
Proceeds from Issuance of Private Placement	$ 33,300
Investment Owned, Cost	$ 15,000

SCHEDULE OF POTENTIALLY DILUTIV

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,419,391	16,840,698
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		3,312,696
Common Stock Equivalent Of Series A Through K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		8,558,947
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,201,019	3,962,074
Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,034,979	823,129
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	113,500
Stock Warrants Issuable Upon Conversion Of Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	69,893	183,852

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Deferred offering costs	$ 303
Fair Value, Inputs, Level 3 [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant liabilities		$ 169
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Deferred offering costs	$ 1,871	$ 1,568

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,703	$ 3,594
Less: accumulated depreciation and amortization	(3,086)	(2,950)
Property and equipment, net	617	644
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	148	148
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,762	2,762
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	127	127
Leaseholds and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	557	557
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 109

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 136	$ 138

ACCRUED COMPENSATION (Details N

ACCRUED COMPENSATION (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued Compensation
Accrued compensation	$ 2,910	$ 2,852

LEASE LIABILITIES (Details Narr

LEASE LIABILITIES (Details Narrative) - USD ($) $ in Thousands	1 Months Ended					3 Months Ended
	Feb. 28, 2023	Apr. 30, 2022	Jul. 31, 2021	Dec. 31, 2020	Jul. 31, 2018	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Aggregate average monthly payments	$ 30		$ 10	$ 18	$ 10
Option to extend lease	extended the lease through December 2024, with no changes to any of the other terms of the lease	the option to extend the lease for an additional five years			option to extend for an additional five years.
Operating lease right of use asset	$ 649	$ 860	656	439		$ 1,851		$ 1,335
Operating lease liability	$ 649	$ 860	$ 656	$ 12	$ 174	1,950		$ 1,164
Operating lease discount rate	5.50%	4%	4%	4%	4%
Increase in lease liability	$ 637	$ 686				(114)	$ (80)
Payment for operating lease						114	80
Amortization of right of use assets						118	102
Rent expense						$ 9	$ 9
Accounting Standards Update 2016-02 [Member]
Operating lease right of use asset					$ 518
Operating lease liability				$ 439	$ 519

SCHEDULE OF WARRANTS (Details)

SCHEDULE OF WARRANTS (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares
Exercise price	$ 6
Expected dividends
Expected volatility	96%
Risk free interest rate	3.50%
Life of the warrants	3 years

NOTES PAYABLE _ SHAREHOLDERS (D

NOTES PAYABLE – SHAREHOLDERS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Outstanding principal amount	$ 200,000		$ 1,100,000
Accrued and unpaid interest	51,000		5,000
Borrowings	900,000
Repayment of debt	400,000
Debt instrument, interest amount	1,000
Accrued interest	47,000
Outstanding principal amount	$ 1,600,000
Description of warrants	Company issued the note holders stock warrants to purchase up to an aggregate total of 44,441 shares of its common stock with an exercise price per share equal to 90% of the IPO price, or $5.40 per share, based on the IPO closing price
Fair value of warrants	$ 3,110,000
Debt discount of issuance amount	169,000
Amortized debt discount	108,000		61,000
Unamortized debt discount	0		108,000
Note Holders [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value of warrants	$ 169,000
IPO [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued	44,441
Note Payable Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Note payable			$ 1,100,000
Notes accrued interest			12%

SCHEDULE OF CONVERTIBLE NOTES_2

SCHEDULE OF CONVERTIBLE NOTES PAYABLE TO SHAREHOLDERS (Details) - USD ($) $ in Thousands	Mar. 31, 2023		Jan. 30, 2023	Dec. 31, 2022		Dec. 31, 2021	Apr. 30, 2018	Dec. 31, 2016	Apr. 30, 2016
Short-Term Debt [Line Items]
Convertible notes payable - shareholders	$ 65			$ 15,407
Less: current portion	(65)			(15,407)
Convertible notes payable – shareholders – long - term portion
Convertible Notes Payable Shareholder One [Member]
Short-Term Debt [Line Items]
Convertible notes payable - shareholders	65	[1]	$ 7,778	7,838	[1]			$ 7,988
Convertible Notes Payable Shareholder Two [Member]
Short-Term Debt [Line Items]
Convertible notes payable - shareholders		[2]	1,500	1,500	[2]				$ 2,661
Convertible Notes Payable Shareholder Three [Member]
Short-Term Debt [Line Items]
Convertible notes payable - shareholders		[3]	700	700	[3]		$ 700
Convertible Notes Payable Shareholder Four [Member]
Short-Term Debt [Line Items]
Convertible notes payable - shareholders		[4]	$ 5,369	$ 5,369	[4]	$ 5,369
[1]During the years ended December 31, 2011 through 2016, the Company entered into convertible note payable agreements with individuals aggregating to a total amount of $ 7,988 8 25.73 2,661 11.51 6.78 10 6.78 700 5.0 12.00 90 25 10.50 three years 5,369 5.0 12.00 90 25 10.50 three years

SCHEDULE OF CONVERTIBLE NOTES_3

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Convertible notes payable, net		$ 8,524
Less: debt discount		(541)
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes payable, net		$ 9,065

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)		3 Months Ended
	Jan. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Jan. 10, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Short-Term Debt [Line Items]
Principal amount owed on notes		$ 65,000			$ 15,407,000
Accrued interest		10,000
Unamortized debt discount		0			108,000
Amortized debt discount		649,000	$ 49,000
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Principal amount owed on notes	$ 9,065,000				9,065,000
Conversion price				$ 10.50
Accrued and unpaid interest	$ 1,223,000				1,178,000
Accrued interest		45,000
Unamortized debt discount		0			$ 541,000
Amortized debt discount		$ 541,000
Debt conversion shares issued	979,619
Convertible Note Payable Agreements [Member]
Short-Term Debt [Line Items]
Principal amount owed on notes						$ 9,065,000	$ 9,065,000
Accrued interest percentage						6%	6%
Conversion price						$ 10.50	$ 10.50
Warrants to purchase shares						146,641	146,641
Warrants exercise price						$ 10.50	$ 10.50

SCHEDULE OF PREFERRED STOCK (De

SCHEDULE OF PREFERRED STOCK (Details)	Dec. 31, 2022 $ / shares shares
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	29,927,994
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 22,095
Preferred stock, shares issued	22,094,889
Preferred stock, shares outstanding	22,094,889
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	4,500,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 4,500
Preferred stock, shares issued	4,500,000
Preferred stock, shares outstanding	4,500,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	608,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 608
Preferred stock, shares issued	608,000
Preferred stock, shares outstanding	608,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	5,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 5,000
Preferred stock, shares issued	5,000,000
Preferred stock, shares outstanding	5,000,000
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	3,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 3,000
Preferred stock, shares issued	3,000,000
Preferred stock, shares outstanding	3,000,000
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	1,591,994
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 1,592
Preferred stock, shares issued	1,591,994
Preferred stock, shares outstanding	1,591,994
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	953,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 953
Preferred stock, shares issued	953,000
Preferred stock, shares outstanding	953,000
Series H Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	5,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 536
Preferred stock, shares issued	536,000
Preferred stock, shares outstanding	536,000
Series I Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	2,775,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 2,757
Preferred stock, shares issued	2,757,442
Preferred stock, shares outstanding	2,757,442
Series J Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	2,500,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 1,282
Preferred stock, shares issued	1,281,600
Preferred stock, shares outstanding	1,281,600
Series K Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	4,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 1,867
Preferred stock, shares issued	1,866,853
Preferred stock, shares outstanding	1,866,853

SCHEDULE OF RESTRICTED COMMON S

SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of restricted shares, beginning | shares
Fair value, beginning | $
Weighted average grant date fair value, beginning | $ / shares
Number of restricted shares, granted | shares	113,500
Fair value, granted | $	$ 746
Weighted average grant date fair value, granted | $ / shares	$ 6.57
Number of restricted shares, vested | shares
Fair value, vested | $	$ (198)
Weighted average grant date fair value, vested | $ / shares	$ 6.57
Number of restricted shares, forfeited | shares
Fair value, forfeited | $
Weighted average grant date fair value, forfeited | $ / shares
Number of restricted shares, ending | shares	113,500
Fair value, ending | $	$ 548
Weighted average grant date fair value, ending | $ / shares	$ 6.57

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Number of options shares, beginning | shares	4,201,019
Weighted average exercise price, beginning	$ 6.09
Number of options shares, granted | shares
Weighted average exercise price, granted
Number of options shares, cancelled | shares
Weighted average exercise price, cancelled
Number of options shares, exercised | shares
Weighted average exercise price, exercised
Number of options shares, expired | shares
Weighted average exercise price, expired
Number of options shares, ending | shares	4,201,019
Weighted average exercise price, ending	$ 6.09
Number of options shares, exercisable | shares	4,012,963
Weighted average exercise price, exercisable ending	$ 6.26
Number of options shares, unvested, ending | shares	188,056
Exercise price range, unvested ending	$ 6
Weighted average exercise price, unvested ending	6
Minimum [Member]
Exercise price range, beginning	6
Exercise price range, ending	6
Exercise price range, exercisable ending	6
Maximum [Member]
Exercise price range, beginning	10.50
Exercise price range, ending	10.50
Exercise price range, exercisable ending	$ 10.50

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 6
Options outstanding number of outstanding | shares	4,092,887
Options outstanding average remaining contractual life	5 years 3 months 10 days
Options outstaning weighted average exercise price	$ 6
Options exercisable number of outstanding | shares	3,904,831
Options exercisable average remaining contractual life	5 years 1 month 9 days
Options exercisable weighted average exercise price	$ 6
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 10.50
Options outstanding number of outstanding | shares	108,132
Options outstanding average remaining contractual life	4 years 9 months 18 days
Options outstaning weighted average exercise price	$ 9.67
Options exercisable number of outstanding | shares	108,132
Options exercisable average remaining contractual life	4 years 9 months 18 days
Options exercisable weighted average exercise price	$ 9.67
Range of exercise prices, lower limit	9
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 10.50
Options outstanding number of outstanding | shares	4,201,019
Options outstanding average remaining contractual life	5 years 3 months 7 days
Options outstaning weighted average exercise price	$ 6.09
Options exercisable number of outstanding | shares	4,012,963
Options exercisable average remaining contractual life	5 years 1 month 9 days
Options exercisable weighted average exercise price	$ 6.26
Range of exercise prices, lower limit	$ 6

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Number of warrant shares, beginning | shares	725,174
Weighted average exercise price, beginning	$ 8.24
Number of warrant shares, granted | shares	331,269
Weighted average exercise price, granted	$ 7.44
Number of warrant shares, cancelled | shares	(36)
Exercise price range range per share, cancelled	$ 9
Weighted average exercise price, cancelled	$ 9
Number of warrant shares, exercised | shares	(16,666)
Exercise price range range per share, exercised	$ 9
Weighted average exercise price, exercised	$ 9
Number of warrant shares, expired | shares	(4,762)
Exercise price range range per share, expired	$ 10.50
Weighted average exercise price, expired	$ 10.50
Number of warrant shares, ending | shares	1,034,979
Weighted average exercise price, ending	$ 7.96
Number of warrant shares, exercisable | shares	1,034,979
Weighted average exercise price, exercisable	$ 7.96
Minimum [Member]
Exercise price range range per share, beginning	3
Exercise price range range per share, granted	5.40
Exercise price range range per share, ending	3
Exercise price range range per share, exercisable	3
Maximum [Member]
Exercise price range range per share, beginning	10.50
Exercise price range range per share, granted	10.50
Exercise price range range per share, ending	10.50
Exercise price range range per share, exercisable	$ 10.50

SCHEDULE OF OUTSTANDING AND E_2

SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants Outstanding number of outstanding	1,034,979	725,174
Warrants outstaning weighted average exercise price	$ 7.96	$ 8.24
Warrants exercisable number of outstanding	1,034,979
Warrants exercisable weighted average exercise price	$ 7.96
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 3
Warrants Outstanding number of outstanding	133,333
Warrants outstanding average remaining contractual life	3 years 11 months 1 day
Warrants outstaning weighted average exercise price	$ 3
Warrants exercisable number of outstanding	133,333
Warrants exercisable average remaining contractual life	3 years 11 months 1 day
Warrants exercisable weighted average exercise price	$ 3
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 9
Warrants Outstanding number of outstanding	627,940
Warrants outstanding average remaining contractual life	3 years 2 months 8 days
Warrants outstaning weighted average exercise price	$ 7.91
Warrants exercisable number of outstanding	627,940
Warrants exercisable average remaining contractual life	3 years 2 months 8 days
Warrants exercisable weighted average exercise price	$ 7.91
Range of exercise prices, lower limit	5.40
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 10.50
Warrants Outstanding number of outstanding	273,706
Warrants outstanding average remaining contractual life	1 year 4 months 28 days
Warrants outstaning weighted average exercise price	$ 10.50
Warrants exercisable number of outstanding	273,706
Warrants exercisable average remaining contractual life	1 year 4 months 28 days
Warrants exercisable weighted average exercise price	$ 10.50
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 10.50
Warrants Outstanding number of outstanding	1,034,979
Warrants outstanding average remaining contractual life	2 years 9 months 25 days
Warrants outstaning weighted average exercise price	$ 7.96
Warrants exercisable number of outstanding	1,034,979
Warrants exercisable average remaining contractual life	2 years 9 months 25 days
Warrants exercisable weighted average exercise price	$ 7.96
Range of exercise prices, lower limit	$ 3

SHAREHOLDERS_ EQUITY (Details N

SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

Feb. 17, 2023

Jan. 30, 2023

Sep. 30, 2018

May 15, 2023

Feb. 28, 2023

Sep. 30, 2022

Jun. 30, 2022

Sep. 30, 2018

Mar. 31, 2023

Mar. 31, 2022

Dec. 31, 2022

Aug. 31, 2009

Class of Stock [Line Items]

Preferred stock, shares outstanding

22,094,889

Conversion of common stock

8,355,610

Conversion price adjustment

991,172

Common stock, shares authorized

75,000,000

75,000,000

Common stock, shares issued

24,553,470

9,126,726

Common stock, shares outstanding

24,553,470

9,126,726

Gross proceeds of the IPO

$ 12,632

Issuance of restricted shares

113,500

Fair value granted

$ 746

Stock compensation

198

Unamortized compensation

$ 548

Fair market value of shares percentage, description

(i) 100% of the fair market value of a share of stock on the grant date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company.

Repricing costs

$ 2,733

$ 2,606

Share compensation

227

Unvested compensation

1,751

Aggregate intrinsic value outstanding

90,933

Fair value of warrants

3,110

Aggregate intrinsic value of warrants

$ 13,745

Subsequent Event [Member]

Class of Stock [Line Items]

Exercise of warrants shares

111,828

Proceeds from warrant exercises

$ 1,174

Convertible Debt Agreements [Member]

Class of Stock [Line Items]

Exercise of warrants shares

69,893

Warrants to purchase shares, percentage

25%

Warrant [Member]

Class of Stock [Line Items]

Fair value of warrants

$ 3,110

Exercise Price Range Two [Member]

Class of Stock [Line Items]

Range of exercise prices, lower limit

$ 9

Range of exercise prices, upper limit

$ 10.50

Options outstanding number of outstanding

108,132

Exercise Price Range One [Member]

Class of Stock [Line Items]

Range of exercise prices, upper limit

$ 6

Options outstanding number of outstanding

4,092,887

Maximum [Member] | Convertible Debt Agreements [Member]

Class of Stock [Line Items]

Exercise price

$ 10.50

Minimum [Member] | Convertible Debt Agreements [Member]

Class of Stock [Line Items]

Exercise price

$ 9

Director [Member]

Class of Stock [Line Items]

Issuance of restricted shares

113,500

Fair value granted

$ 746

Executive Officers and Directors [Member] | Exercise Price Range One [Member]

Class of Stock [Line Items]

Options outstanding number of outstanding

2,796,400

Lender [Member]

Class of Stock [Line Items]

Exercise of warrants shares

111,828

Exercise price

$ 10.50

Lender [Member] | Warrant [Member]

Class of Stock [Line Items]

Exercise of warrants shares

44,441

Exercise price

$ 5.40

Warrant Holder [Member] | Warrant [Member]

Class of Stock [Line Items]

Exercise of warrants shares

16,666

Exercise price

$ 9

Common stock issued

11,666

2022 Plan [Member]

Class of Stock [Line Items]

Shares of common stock issued

2,800,000

Number of shares of common stock percentage

5%

Shares available for grant

2,800,000

2022 Employee Stock Purchase Plan [Member]

Class of Stock [Line Items]

Shares of common stock issued

770,000

Number of shares of common stock percentage

1%

Increase shares of common stock

2,100,000

2009 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Common stock shares authorized

6,166,666

Additional shares authorized

3,774,260

2019 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Shares of common stock issued

2,059,073

Shares available for grant

1,632,314

2019 Equity Incentive Plan [Member] | Maximum [Member]

Class of Stock [Line Items]

Shares of common stock issued

5,833,333

IPO [Member]

Class of Stock [Line Items]

Common stock issued and sold

2,500,000

153,000

Sale of stock per share

$ 6

$ 6

Gross proceeds of the IPO

$ 15,918

Proceeds after deducting underwriting discounts and commissions and offering expenses payable

$ 12,632

IPO [Member] | Warrant [Member]

Class of Stock [Line Items]

Exercise of warrants shares

175,000

Exercise price

$ 6

Series A Through K Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares outstanding

22,094,889

0

22,094,889

Series H Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares outstanding

536,000

Conversion price adjustment

272,101

Undeclared and unpaid shares earned

$ 3,443

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	May 12, 2023	May 15, 2023	Mar. 31, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Bridge Loan			$ 210,000
Debt Instrument, Face Amount			200,000	$ 1,100,000
Debt Instrument, Increase, Accrued Interest			$ 10,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		111,828
Proceeds from Warrant Exercises		$ 1,174,000
Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Shares, Issued	1,665,213
Share Price	$ 20
Proceeds from Issuance of Private Placement	$ 33,300
Investment Owned, Cost	$ 15,000